StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > BioPub Webcast

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Feb 18, 2022 6:28pm

144 Views

Post# 34443725

RE:RE:RE:RE:RE:RE:BioPub Webcast

27% of Canadians who filed make over 80k. That's millions of Canadians. I understand the test may be too expensive for many but not for millions and that's 10s of millions in the US and UK

And those private clinics I posted about earlier are growing and opening up additional locations and those are 3-5k a year.

For those with the means there is a market for Aristotle

TrippinAgain123 wrote: Maybe your rich but many average Canadians are struggling to get by and would rather opt on something free and use the 2k for their family in most cases, this is a reality.

<< Previous

Bullboard Posts

Next >>

Umicore hits pause on Canadian battery materials plant construction